A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy

Journal of Immunotherapy

Volumn 15, Issue 1, 1994, Pages 22-28

  Pockaj, Barbara A ^a   Yang, James C ^a,b   Lotze, Michael T ^a   Lange, Julie R ^a   Spencer, William F ^a   Steinberg, Seth M ^b   Topalian, Suzanne L ^a   Schwartzentruber, Douglas J ^a   White, Donald E ^a   Rosenberg, Steven A ^a  

^a Laboratory of Leukocyte Biology   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Colloid; Crystalloid; Interleukin 2; Shock; Vascular leak syndrome

Indexed keywords

ALBUMIN; ALPHA INTERFERON; CREATININE; DOPAMINE; HEMOGLOBIN; HUMAN SERUM ALBUMIN; INTERLEUKIN 4; PHENYLEPHRINE; PROTEIN; RECOMBINANT INTERLEUKIN 2; SODIUM CHLORIDE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BOLUS INJECTION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLLOID; CRYSTALLOID; DRUG COST; FEMALE; FLUID THERAPY; HUMAN; HYPOALBUMINEMIA; HYPOPROTEINEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; OLIGURIA; PRIORITY JOURNAL; RESUSCITATION; SCHOOL CHILD; SHOCK; TACHYCARDIA; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; CHILD; COLLOIDS; FEMALE; FLUID THERAPY; HUMAN; HYPOTENSION; INTERLEUKIN-2; MALE; MIDDLE AGE; OLIGURIA; PLASMA SUBSTITUTES; PROSPECTIVE STUDIES; RESUSCITATION; SYNDROME; TACHYCARDIA;

EID: 0027980054     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199401000-00003     Document Type: Article

References (18)

1. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-76.
2. Rosenberg SA. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In: DeVita VT, Jr., Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: JB Lippin-cott, 1986;55-61.
3. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-83.
4. Margolin KA, Rayner AA, Hawkins MJ, et al. Toxicities and management of interleukin-2 and lymphokine activated killer cell therapy of solid tumors. J Clin Oncol 1989;7:480-98.
5. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704.
6. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 1986;135:1735-12.
7. Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989;7:7-20.
8. Ognibene FP, Rosenberg SA, Lotze MT, et al. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 1988;94:750-4.
9. Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Seipp CA, Rosenberg SA. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986;58:2764-72.
10. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
11. Gammage G. Crystalloid versus colloid: is colloid worth the cost? Int Anesthesiol Clin 1987;25:37-60.
12. Velanovich V. Crystalloid versus colloid fluid resuscitation: a meta-analysis of mortality. Surgery 1989;105:65-71.
13. Goodwin CW, Dorethy J, Lam V, Pruitt BA. Randomized trial of efficacy of crystalloid and colloid resuscitation on hemodynamic response and lung water following thermal injury. Ann Surg 1983;197:520-31.
14. Rackow EC, Falk JL, Fein IA, Seigel JS, Packman MI, Haupt MT, et al. Fluid resuscitation in circulatory shock: a controlled clinical trial. Surgery 1981;89:434-8.
15. Virgilio RW, Rice CL, Smith DE, et al. Crystalloid versus colloid resuscitation: is one better? Surgery 1979;85:129-39.
16. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-74.
17. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Special Report. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988;319:1676-80.
18. Moss GS, Lowe RJ, Jilek J, Levine HD. Colloid or crystalloid in the resuscitation of hemorrhagic shock: a controlled clinical trial. Surgery 1981;89:434-8.